Company Filing History:
Years Active: 1995-1999
Title: Ray F Ebert: Innovator in Bladder Cancer Treatment
Introduction
Ray F Ebert is a notable inventor based in Derwood, MD (US). He has made significant contributions to the field of immunotherapy, particularly in the treatment of bladder cancer. With a total of 4 patents, Ebert's work focuses on enhancing the effectiveness of keyhole limpet hemocyanin (KLH) compositions.
Latest Patents
Ebert's latest patents include a method for treating bladder cancer using a stabilized KLH composition. This invention is characterized by its intact non-degraded subunit, which has a molecular weight of approximately 400,000 based on SDS-PAGE analysis. The composition contains at least 50% didecameric or higher KLH multimers, as determined by sedimentation-equilibrium and sedimentation-velocity ultracentrifugation analyses. The KLH composition is stabilized at 4°C by dissolving and storing it in an isotonic buffer that preferably contains calcium and magnesium. It is crucial that the KLH not be frozen or lyophilized during its preparation or storage. This composition demonstrates enhanced immunogenic activity, particularly anti-tumor activity, which is significantly reduced if the KLH is frozen or lyophilized. The KLH composition exhibits enhanced anti-tumor activity in a murine bladder tumor model, representing a new and useful anti-tumor immunotherapeutic agent.
Career Highlights
Throughout his career, Ray F Ebert has worked with various companies, including Per Immune Holdings, Inc. and Akzo N.V. His innovative approaches have contributed to advancements in cancer treatment and immunotherapy.
Collaborations
Ebert has collaborated with notable individuals in his field, including Richard D Swerdlow and Rafael P Valdes-Camin. These collaborations have further enriched his research and development efforts.
Conclusion
Ray F Ebert's contributions to the field of immunotherapy, particularly in bladder cancer treatment, highlight his innovative spirit and dedication to improving patient outcomes. His work continues to pave the way for advancements in cancer therapies.